ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation

Oncology Reports

Volumn 25, Issue 3, 2011, Pages 693-699

  De Castro Jr , Gilberto ^a   Pasini, Fatima Solange ^b   Siqueira, Sheila Aparecida Coelho ^b   Ferraz, Alberto Rossetti ^b   Villar, Rosangela Correa ^b   Snitcovsky, Igor Moysés Longo ^b   Federico, Miriam Hatsue Honda ^b  

^a Instituto do Cancer do Estado de Sao Paulo   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chemoradiation; Cisplatin; Excision repair cross complementation group 1; Head and neck squamous cell carcinoma; Single nucleotide polymorphisms

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; DNA POLYMORPHISM; FEMALE; GENOTYPE; H SCORE; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79551590004     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1133     Document Type: Article

References (38)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
2. Cooper JS, Pajak TF, Forastiere AA, et al: Prospective concurrent radiotherapy and chemotherapy for high-risk squamouscell carcinoma of the head and neck. N Engl J Med 350: 1937-1944, 2004.
3. Bernier J, Domenge C, Ozsahin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350: 1945-1952, 2004.
4. Fietkau R, Lautenschläger C, Sauer R, et al: Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck: results of the German phase III trial ARO 96-3. J Clin Oncol 24 (Suppl. 18): 5507, 2006.
5. Bernier J, Cooper JS, Pajak TF, et al: Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27: 843-850, 2005.
6. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007.
7. Niedernholfer LJ, Odijk H, Budzowska M, et al: The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24: 5776-5787, 2004.
8. Handra-Luca A, Hernandez J, Mountzios G, et al: Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 13: 3855-3859, 2007.
9. Warnecke-Eberz U, Metzger R, Miyazono F, et al: High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 10: 3794-3799, 2004.
10. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006.
11. Cobo M, Isla D, Massuti B, et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25: 2747-2754, 2007.
12. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT and Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63: 1311-1316, 2003.
13. Simon GR, Sharma S, Cantor A, Smith P and Bepler G: ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127: 978-983, 2005.
14. Zheng Z, Chen T, Li X, Haura E, Sharma A and Bepler G: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356: 800-808, 2007.
15. Gazdar AF: DNA repair and survival in lung cancer, the two faces of Janus. N Engl J Med 356: 771-773, 2007.
16. Li XQ, Li J, Shi SB, Chen P, Yu LC and Bao QL: Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in nonsmall cell lung cancer patients receiving postoperative cisplatinbased chemotherapy. Int J Biol Markers 24: 230-237, 2009.
17. Moreno V, Gemignani F, Landi S, et al: Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 12: 2101-2108, 2006.
18. Chang MHC, Tzeng CH, Chen PM, et al: ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with meta-static colorectal carcinoma. Cancer Sci 100: 278-283, 2009.
19. Ryu JS, Hong YC, Han HS, et al: Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44: 311-316, 2004.
20. Carles J, Monzo M, Amat M, et al: Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys 66: 1022-1030, 2006.
21. Krivak TC, Darcy KM, Tian C, et al: Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 26: 3598-3606, 2008.
22. Abboud O, Weng X, Guertin L, et al: ERCC1 polymorphism in patients with locally advanced head and neck squamous cell carcinoma treated with concomitant chemoradiation: prevalence and impact on treatment efficacy. J Clin Oncol 27(Pt I): 309s, 2009.
23. Al-Haddad S, Zhang Z, Levgue E, et al: Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol 155: 2057-2066, 1999.
24. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
25. Jun HJ, Ahn MJ, Kim HS, et al: ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 99: 167-172, 2008.
26. Fountzilas G, Bamias A, Kalogera-Fountzila A, et al: Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable nonnasopharyngeal carcinoma of the head and neck. Anticancer Res 29: 529-538, 2009.
27. Koh Y, Kim TM, Jeon YK, et al: Class III β-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol 20: 1414-1419, 2009.
28. Fountzilas G, Kalogera-Fountzila A, Lambaki S, et al: MMP9 but not EGFR, MET, ERCC1, P16, and P-53 is associated with response to concomitant radiotherapy, cetuximab, and weekly cisplatin in patients with locally advanced head and neck cancer. J Oncol 2009: 305908, 2009.
29. Akita H, Zheng Z, Takeda Y, et al: Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 28: 2903-2909, 2009.
30. Yang J, Liu X, Niu P, et al: Dynamic changes of XPA, XPC, XPF, XPG and ERCC1 protein expression and their correlation with levels of DNA damage in human bronchial epithelia cells exposed to benzo[a]pyrene. Toxicol Lett 174: 10-17, 2007.
31. Baek SK, Kim SY, Lee JJ, Kim YM, Yoon HJ and Cho KS: Increased ERCC1 expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. Cancer Res Treat 38: 19-24, 2006.
32. Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD and Niedernhofer LJ: Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res 69: 6831-6838, 2009.
33. Kwon MJ, Oh E, Lee S, et al: Identification of novel reference genes using multiplatform expression data and their validation for quantitative gene expression analysis. PLoS One 4: e6162, 2009.
34. Warnecke-Eberz U, Vallböhmer D, Alakus H, et al: ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J Gastrointest Surg 13: 1411-1421, 2009.
35. Smith S, Su D, Rigault de la Longrais IA, et al: ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based chemotherapy. J Clin Oncol 25: 5172-5179, 2007.
36. Isla D, Sarries C, Rosell R, et al: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15: 1194-1203, 2004.
37. Woelfelschneider A, Popanda O, Lilla C, et al: A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients. Carcinogenesis 29: 1758-1764, 2008.
38. Quintela-Fandino M, Hitt R, Medina PP, et al: DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 24: 4333-4339, 2006.